Feb 20, 2025 13:29 JST

Source: Eisai

Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives

TOKYO, Feb 20, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for “Human CapitalLeaders 2024” and “Human Capital Management Gold Quality” in the “Human Capital Survey 2024” jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.), MS&AD InterRisk Research & Consulting, Inc. and Association to Confirm the Human Investment Value for Enterprise. This is the second consecutive year that Eisai has been selected.

In the “Human Capital Survey 2024” (conducted between August and December 2024), 17 highly rated companies were selected for “Human Capital Management Gold Quality”, and 10 companies that were recognized by experts as having made particularly outstanding efforts were selected as “Human Capital Leaders 2024” out of approximately 400 participating companies and organizations. Eisai was highly evaluated for its various initiatives implementing human capital management aligned with its Articles of Incorporation based on detailed analysis of its current situation and future aspirations, proactive information disclosure with unique performance indicators such as employee impact accounting, as well as its measures for facilitating smooth internal communication.

To increase the value of our employees, Eisai made a partial amendment to the Articles of Incorporation at an Ordinary GeneralMeeting of Shareholders in 2022, clearly stating that it will strive to “ensure stable employment”, “respect human rights and diversity”, “provide full opportunities for growth to support self- fulfillment”, and “create an employee-friendly environment”. Eisai has also reinforced its human resource initiatives, including the formulation of an “Integrated Human Resource Strategy”, with the pillars of “Wellbeing including health of employees”, “Diverse work style”, “Development and growth of employees”, and “Growth ofthe organization and businesses”, as well as introducing a compensation system based on employee roles since 2023, along with a personnel assessment system putting high value on employee actions with the aim of encouraging employees to growautonomously and motivate them to serve in higher positions. Eisai promotes proactive information disclosure regarding its initiatives on human capital management in its “Value Creation Report” and its corporate website’s “Sustainability” section, as wellas its “Human Capital Report” which has been published since 2023 summarizing its human capital initiatives and KPI linked to its human resource strategies.

Eisai is seeking to provide impact to not only our shareholders, but various stakeholders including our customers and local communities by delivering new value to patients and the people in the daily living domain through the activities of our employees who are the only stakeholders who can directly contribute to our corporate concept, human health care.

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
 
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
 
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
 
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
 
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
 
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
More Press release >>

Latest Press Release


More Latest Release >>